Latest stories on PAVM
PAVmed targets Varis FDA submission by end of 2026 while evaluating new assets following cap table cleanup
Seeking Alpha58 · neutralearnings
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
PAVmed (PAVM) Q4 2025 Earnings Transcript
Yahoo Finance53 · neutralearnings
PAVmed Non-GAAP EPS of -$1.17 misses by $0.48, revenue of $0.02M misses by $0.08M
Seeking Alpha33 · bearishearnings